Evidence map›Paper›PMID 24116088›Full record

ArticlePloS one2013

Significant biochemical, biophysical and metabolic diversity in circulating human cord blood reticulocytes.

Benoît Malleret, Fenggao Xu, Narla Mohandas, Rossarin Suwanarusk, Cindy Chu, Juliana A Leite, Kayen Low, Claudia Turner, Kanlaya Sriprawat, Rou Zhang and 9 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03957915 (A Phase I, First in Human, Open-label Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia), which is not on this map. Cited by 80 papers.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03957915 early_phase1completednot on this mapstarted 2020, after this paper: background citation

A Phase I, First in Human, Open-label Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia

TypeinterventionalSponsorInstitut Paoli-CalmettesRan2020 to 2025Enrolled33ConditionsAcute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukaemia RecurrentArmsINA03 administration
3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 148 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Cells · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 6 countries.

Benoît MalleretLaboratory of Malaria Immunobiology, Singapore Immunology Network (SIgN), Agency for Science Technology and Research (ASTAR), Biopolis, Singapore.
Fenggao Xu
Narla Mohandas
Rossarin Suwanarusk
Cindy Chu
Juliana A Leite
Kayen Low
Claudia Turner
Kanlaya Sriprawat
Rou Zhang
Olivier Bertrand
Yves Colin
Fabio T M Costa
Choon Nam Ong
Mah Lee Ng
Chwee Teck Lim
Francois Nosten
Laurent Rénia
Bruce Russell
National University of Singapore · SGShoklo Malaria Research Unit · THSingapore Immunology Network · SGUniversidade Estadual de Campinas (UNICAMP) · BRAgency for Science, Technology and Research · SGChurchill Hospital · GBInstitut National de la Transfusion Sanguine · FRNew York Blood Center · USSingapore-MIT Alliance for Research and Technology · SGUniversité Paris Cité · FR

Funding

RED CELL DEFORMABILITY IN VITRO AND SURVIVAL IN VIVOR37DK026263 · NIDDK · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI NARLA, MOHANDAS · 1995 to 2017
$4.5M
NIDDK NIH HHS R37 DK026263Wellcome Trust 089275
6 · The paper itself

Abstract

backgroundThe transition from enucleated reticulocytes to mature normocytes is marked by substantial remodeling of the erythrocytic cytoplasm and membrane. Despite conspicuous changes, most studies describe the maturing reticulocyte as a homogenous erythropoietic cell type. While reticulocyte staging based on fluorescent RNA stains such as thiazole orange have been useful in a clinical setting; these 'sub-vital' stains may confound delicate studies on reticulocyte biology and may preclude their use in heamoparasite invasion studies. DESIGN AND

methodsHere we use highly purified populations of reticulocytes isolated from cord blood, sorted by flow cytometry into four sequential subpopulations based on transferrin receptor (CD71) expression: CD71high, CD71medium, CD71low and CD71negative. Each of these subgroups was phenotyped in terms of their, morphology, membrane antigens, biomechanical properties and metabolomic profile.

resultsSuperficially CD71high and CD71medium reticulocytes share a similar gross morphology (large and multilobular) when compared to the smaller, smooth and increasingly concave reticulocytes as seen in the in the CD71low and CD71negativesamples. However, between each of the four sample sets we observe significant decreases in shear modulus, cytoadhesive capacity, erythroid receptor expression (CD44, CD55, CD147, CD235R, and CD242) and metabolite concentrations. Interestingly increasing amounts of boric acid was found in the mature reticulocytes.

conclusionsReticulocyte maturation is a dynamic and continuous process, confounding efforts to rigidly classify them. Certainly this study does not offer an alternative classification strategy; instead we used a nondestructive sampling method to examine key phenotypic changes of in reticulocytes. Our study emphasizes a need to focus greater attention on reticulocyte biology.

Indexed as

Antigens, CDFetal BloodFlow CytometryHumansReticulocytesAntigens, CD

Identifiers

PMID24116088
PMCPMC3793000
OpenAlexW2031914759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.